(Sharecast News) - Drugmaker Hikma Pharmaceuticals turned in a solid first half on Thursday, with group revenues rising 4% to $1.73bn, driven by a strong performance in its branded unit and stable contributions from both injectables and Hikma Rx.
Hikma said branded revenue jumped 15% to $502m, while injectables and Hikma...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE